ChinaBio® Partnering Forum 2017: Rapid change: Good times for pharma?

June 5, 2017
Everything in China seems to be on the fast track. This is especially true in the pharma industry, where new announcements affecting regulations, pricing, and reimbursement are occurring on nearly a daily basis. How are Western pharma companies reacting to these changes? Is it going to be easier and faster to gain approval for Western drugs in China? Will this stimulate or impede local R&D and partnering activity?
Previous Video
ChinaBio® Partnering Forum 2017: Funding drug development in China through VCs and partnerships
ChinaBio® Partnering Forum 2017: Funding drug development in China through VCs and partnerships

Western and China companies are leveraging the significant funding and support available in China to develo...

Next Article
Biotech Startups: Land and conduct a successful investor meeting
Biotech Startups: Land and conduct a successful investor meeting

Biotech startup companies face many challenges, but one of the most common is landing and conducting meetin...